INTRODUCTION
The American Academy of Pediatrics (AAP) recommends annual seasonal influenza immunization for all people 6 months and older, including all children and adolescents, during the 2014-2015 influenza season. In addition, special effort should be made to vaccinate people in the following groups:
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(Continued on last page) All children, including infants born preterm, who are 6 months and older with conditions that increase the risk of complications from influenza (eg, children with chronic medical conditions, such as asthma, diabetes mellitus, hemodynamically significant cardiac disease, immunosuppression, or neurologic and neurodevelopmental disorders);
Children of American Indian or Alaska Native heritage All household contacts and out-ofhome care providers of Ø Children with high-risk conditions Ø Children younger than 5 years, especially infants younger than 6 months All health care personnel (HCP) All child care providers and staff All women who are pregnant, are considering pregnancy, are in the postpartum period, or are breastfeeding during the influenza season
KEY POINTS RELEVANT FOR THE 2014-2015 INFLUENZA SEASON
1. Annual seasonal influenza vaccine is recommended for all people 6 months and older, including all children and adolescents, during the 2014-2015 influenza season. It is important that household contacts and out-of-home care providers of children younger than 5 years, especially infants younger than 6 months, and children of any age at high risk of complications from influenza (eg, children with chronic medical conditions, such as asthma, diabetes mellitus, hemodynamically significant cardiac disease, immunosuppression, or neurologic and neurodevelopmental disorders) receive annual influenza vaccine. In the United States, more than two-thirds of children younger than 6 years and almost all children 6 years and older spend significant time in child care or school settings outside the home. Exposure to groups of children increases the risk of contracting infectious diseases. Children younger than 2 years are at elevated risk of hospitalization and complications attributable to influenza. School-aged children bear a large influenza disease burden and have a significantly higher chance of seeking influenza-related medical care compared with healthy adults. Reducing influenza virus transmission (eg, appropriate hand hygiene, respiratory hygiene/ cough etiquette) among children who attend out-of-home child care or school has been shown to decrease the burden of childhood influenza and transmission of influenza virus to household contacts and community members of all ages.
2. The percentage of outpatient visits for influenza-like illness, rates of hospitalization, and deaths attributed to pneumonia and influenza were lower during the 2013-2014 influenza season when compared with the previous season. As of August 23, 2014, 107 laboratoryconfirmed influenza-associated pediatric deaths were reported to the Centers for Disease Control and Prevention (CDC) during the 2013-2014 influenza season. The 2009 influenza A (H1N1) pandemic (pH1N1) viruses predominated, but influenza A (H3N2) and influenza B viruses also were reported in the United States. Of the 107 deaths, 87 were associated with influenza A viruses, and 16 deaths were associated with influenza B viruses. Two deaths were associated with an undetermined type of influenza virus, and 2 deaths were associated with dual infection with both influenza A and B viruses. Although children with certain conditions are at higher risk of complications, 47% of the deaths occurred in children with no high-risk underlying medical condition. Among children hospitalized with influenza and for whom medical chart data were available, approximately 43% had no recorded underlying condition, whereas 26% had underlying asthma or reactive airway disease (Fig 1) . and Evaluation (GRADE) framework, the CDC Advisory Committee on Immunization Practices (ACIP) systematically reviewed the evidence pertaining to the efficacy of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) for healthy children. It concluded that there is greater relative efficacy of LAIV as compared with IIV against laboratoryconfirmed influenza among younger children (based on 2 studies including children up to 6 years of age). The risk of adverse events after immunization, including fever, wheezing, and serious adverse events, appears to be similar for LAIV and IIV. Therefore, LAIV should be considered for healthy children 2 through 8 years of age who have no contraindications or precautions to the intranasal vaccine. If LAIV is not readily available, IIV should be used; vaccination should not be delayed to obtain LAIV. The age of 8 years is selected as the upper limit for this recommendation on the basis of demonstration of superior efficacy of LAIV (ages 2 through 6 years) and for programmatic consistency (8 years is the upper age limit for receipt of 2 doses of influenza vaccine in a previously unvaccinated child).
6. The number of seasonal influenza vaccine doses to be administered in the 2014-2015 influenza season depends on the child' s age at the time of the first administered dose and his or her vaccine history (Fig 2) :
Influenza vaccines are not licensed for administration to infants younger than 6 months.
Children 9 years and older need only 1 dose.
Children 6 months through 8 years of age receiving the seasonal influenza vaccine for the first time should receive a second dose this season at least 4 weeks after the first dose. For the 2014-2015 season, IIVs will be available for intramuscular (IM) injection in both trivalent (IIV3) and quadrivalent (IIV4) formulations. The intranasally administered LAIV will be available only in a quadrivalent formulation (LAIV4). All quadrivalent vaccines will contain the identical influenza strains anticipated to circulate during the 2014-2015 influenza season.
IIVs contain no live virus. IIV3 formulations are available for IM and intradermal (ID) use. The IM formulation of IIV3 is licensed and recommended for children 6 months and older and adults, including people with and without chronic medical conditions. The most common adverse events after IIV administration are local injection site pain and tenderness. Fever may occur within 24 hours after immunization in approximately 10% to 35% of children younger than 2 years but rarely in older children and adults. Mild systemic symptoms, such as nausea, lethargy, headache, muscle aches, and chills, may occur after administration of IIV3.
An ID formulation of IIV3 is licensed for use in people 18 through 64 years of age. ID vaccine administration involves a microinjection with a shorter needle than needles used for IM administration. The most common adverse events are redness, induration, swelling, pain, and itching, which occur at the site of administration; although all adverse events occur at a slightly higher rate with the IM formulation of IIV3, the rate of pain was similar between ID and IM. Headache, myalgia, and malaise may occur and tend to occur at the same rate as that with the IM formulation of IIV3. There is no preference for IM or ID immunization with IIV3 in people 18 years or older. Therefore, pediatricians may choose to use either the IM or ID product for their young adult patients and for any adults they are vaccinating (ie, as part of a cocooning strategy).
IIV4 is available in IM but not ID formulations. One formulation of IIV4 is licensed for use in children as young as 6 months of age. In children, the most common injection site adverse reactions were pain, redness, and swelling. The most common systemic adverse events were drowsiness, irritability, loss of appetite, fatigue, muscle aches, headache, arthralgia, and gastrointestinal tract symptoms. These events were reported with comparable frequency among participants receiving the licensed comparator trivalent vaccines. IIV4 is an acceptable vaccine for people 6 months or older when otherwise appropriate and may offer broader protection than IIV3. The relative quantity of doses of IIV4 that will be available is not certain and likely to be limited. Standard immunization practice should include the ability to respond to acute hypersensitivity reactions. Therefore, influenza vaccine should be given to children with egg allergy with the following preconditions (Fig 3) :
Appropriate resuscitative equipment must be readily available. 3 The vaccine recipient should be observed in the office for 30 minutes after immunization, the usual observation time for receiving immunotherapy.
Providers may consider use of ccIIV3 or RIV3 vaccines produced via nonegg-based technologies for patients 18 years or older with egg allergy in settings in which these vaccines are available and otherwise age appropriate. ccIIV3, which does contain trace amounts of ovalbumin, should be administered according to the guidance for other IIVs (Fig 3) . RIV3, which contains no ovalbumin, may be administered to people with egg allergy of any severity who are 18 through 49 years of age and do not have other contraindications. However, vaccination of patients with mild egg allergy should not be delayed if RIV3 or ccIIV3 is not available. Instead, any licensed, ageappropriate IIV should be used.
VACCINE STORAGE AND ADMINISTRATION
The AAP Storage and Handling Tip Sheet provides resources for practices to develop comprehensive vaccine management protocols to keep the temperature for vaccine storage constant during a power failure or other disaster (www2.aap.org/immunization/ pediatricians/pdf/DisasterPlanning.pdf). a Age indication per package insert is ≥5 y; however, the Advisory Committee on Immunization Practices recommends Afluria not be used in children 6 mo through 8 y of age because of febrile reactions reported in this age group. If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child 5 through 8 y of age who has a medical condition that increases the child' s risk of influenza complications, Afluria can be used; however, pediatricians should discuss with the parents or caregivers the benefits and risks of influenza vaccination with Afluria before administering this vaccine.
Any of the influenza vaccines can be administered at the same visit with all other recommended routine vaccines.
Intramuscular Vaccine
The IM formulation of IIV is shipped and stored at 2°C to 8°C (35°F-46°F). It is administered intramuscularly into the anterolateral thigh of infants and young children and into the deltoid muscle of older children and adults. The volume of vaccine is age dependent; infants and toddlers 6 months through 35 months of age should receive a dose of 0.25 mL, and all people 3 years (36 months) and older should receive 0.5 mL/dose.
Intradermal Vaccine
The ID formulation of IIV also is shipped and stored at 2°C to 8°C (35°F-46°F). It is administered intradermally only to people 18 through 64 years of age, preferably over the deltoid muscle and only using the device included in the vaccine package. Vaccine is supplied in a single-dose, prefilled microinjection system (0.1 mL) for adults. The package insert should be reviewed for full administration details of this product.
Live Attenuated (Intranasal) Vaccine
The cold-adapted, temperature-sensitive LAIV4 formulation currently licensed in the United States must be shipped and stored at 2°C to 8°C (35°F-46°F) and administered intranasally in a prefilled, single-use sprayer containing 0.2 mL of vaccine. A removable dose divider clip is attached to the sprayer to administer 0.1 mL separately into each nostril. After administration of any live virus vaccine, at least 4 weeks should pass before another live virus vaccine is administered.
CURRENT RECOMMENDATIONS
Seasonal influenza immunization is recommended for all children 6 months and older. LAIV should be considered for healthy children 2 through 8 years of age who have no contraindications or precautions to the intranasal vaccine. This is based on a GRADE analysis done by the CDC, which concluded that there is greater relative efficacy of LAIV as compared with IIV against laboratoryconfirmed influenza among younger children. If LAIV is not readily available, IIV should be used; vaccination should not be delayed to obtain LAIV. Particular focus should be on the administration of IIV for all children and adolescents with underlying medical conditions associated with an elevated risk of complications from influenza, including the following:
Asthma or other chronic pulmonary diseases, including cystic fibrosis See Fig 2 for decision algorithm to determine number of doses of seasonal influenza vaccine recommended for children during the 2014-2015 influenza season. c LAIV4 is not recommended for children with a history of asthma. In the 2-through 4-y age group, there are children who have a history of wheezing with respiratory illnesses in whom reactive airway disease is diagnosed and in whom asthma may later be diagnosed. Therefore, because of the potential for increased wheezing after immunization, children 2 through 4 y of age with recurrent wheezing or a wheezing episode in the previous 12 mo should not receive LAIV4. When offering LAIV4 to children in this age group, a pediatrician should screen those who might be at higher risk of asthma by asking the parents or guardians of 2-, 3-, and 4-y-olds (24-through 59-mo-olds) the question, "In the previous 12 months, has a health care professional ever told you that your child had wheezing?" If the parents answer "yes" to this question, LAIV4 is not recommended for these children. d LAIV4 coadministration has been evaluated systematically only among children 12-15 mo of age with measles-mumps-rubella and varicella vaccines. IIV coadministration has been evaluated systematically only among adults with pneumococcal polysaccharide and zoster vaccines. Precautions for administering IIV to presumed egg-allergic children.
PEDIATRICS
influenza vaccine safely during any trimester. Children with an amount of nasal congestion that would notably impede vaccine delivery.
Children 2 through 4 years of age with a history of recurrent wheezing or a medically attended wheezing episode in the previous 12 months because of the potential for increased wheezing after immunization. In this age range, many children have a history of wheezing with respiratory tract illnesses and are eventually diagnosed with asthma. Therefore, when offering LAIV to children 24 through 59 months of age, the pediatrician should screen them by asking the parent or guardian, "In the previous 12 months, has a health care professional ever told you that your child had wheezing?" If a parent answers "yes" to this question, LAIV is not recommended for the child. IIV would be recommended for the child to whom LAIV is not given.
Children with the diagnosis of asthma.
Children with a history of egg allergy. 
VACCINE IMPLEMENTATION
These updated recommendations for prevention and control of influenza in children will have operational and fiscal effects on pediatric practice. Therefore, the AAP has developed implementation guidance on supply, payment, coding, and liability issues; these documents can be found at www.aapredbook.org/implementation.
In addition, the AAP' s Partnership for Policy Implementation has developed a series of definitions using accepted health information technology standards to assist in the implementation of this guideline in computer systems and quality measurement efforts. This document is available at www2.aap. org/informatics/PPI.html.
USE OF ANTIVIRAL MEDICATIONS
Oral oseltamivir remains the antiviral drug of choice for the management of influenza infections. Inhaled zanamivir is an equally acceptable alternative but is more difficult to administer. Antiviral resistance can emerge quickly between seasons. If local or national influenza surveillance data indicate a predominance of a particular influenza strain with a known antiviral susceptibility profile, then empirical treatment can be directed toward that strain. For example, all the influenza A (H3N2) and influenza B viruses tested since October 1, 2013 were sensitive to oseltamivir and zanamivir during the 2013-2014 influenza season. Among the pH1N1 viruses tested for resistance, only 1.2% were found to be resistant to oseltamivir, and none were found to be resistant to zanamivir. In contrast, high levels of resistance to amantadine and rimantadine exist, so these drugs should not be used in the upcoming season unless resistance patterns change significantly.
Current treatment guidelines for antiviral medications (Table 3) are applicable to both infants and children with suspected influenza when known virus strains are circulating in the community or when infants or children are confirmed to have seasonal influenza.
Oseltamivir is available in capsule and oral suspension formulations. The commercially manufactured liquid formulation has a concentration of 6 mg/mL. If the commercially manufactured oral suspension is not available, the capsule may be opened and the contents mixed with simple syrup or Oral-Sweet SF (sugar-free) by retail pharmacies to a final concentration of 6 mg/mL (Table 3) .
Continuous monitoring of the epidemiology, change in severity, and resistance patterns of influenza strains may lead to new guidance.
Treatment should be offered for:
Any child hospitalized with presumed influenza or with severe, complicated, or progressive illness attributable to influenza, regardless of influenza immunization status or whether onset of illness occurred >48 hours before admission.
Influenza infection of any severity in children at high risk of complications of influenza infection (Table 4) , such as children younger than 2 years.
Treatment should be considered for:
Any otherwise healthy child with influenza infection for whom a decrease in duration of clinical symptoms is felt to be warranted by his or her pediatrician. The greatest impact on outcome will occur if treatment can be initiated within 48 hours of illness onset but still should be considered if later in the course of illness.
Reviews of available studies by the CDC, the World Health Organization, and independent investigators have consistently found that timely oseltamivir treatment can reduce the risks of complications, including those resulting in hospitalization and death. Although a 2012 Cochrane review of studies primarily in outpatient settings suggested that oseltamivir may not be effective in preventing complications or hospitalizations from influenza, its authors correctly pointed out that the data reviewed were not always complete, were analyzed in a variety of treated populations, and used a number of clinical trial designs. In addition, a recently revised 2014 Cochrane review of NAIs for influenza further evaluated published and previously unpublished data from randomized clinical trials largely in healthy outpatients with mild illness. Unlike other analyses of the efficacy of antiviral drugs, this Cochrane analysis included both influenza virus-infected and noninfected people with influenza-like illness. Given the specific antiviral activity of NAIs against influenza viruses, this analytic approach underestimates the treatment efficacy of NAIs and their valuable role in helping to lessen complications in those at high risk for them, including hospitalized patients. Furthermore, this review of outpatients was not designed to assess the effect on severe outcomes such as hospitalizations or deaths.
Importantly, treatment with oseltamivir for children with presumed serious, complicated, or progressive disease, irrespective of influenza immunization status or even whether illness began greater than 48 hours before admission, continues to be recommended by the AAP, CDC, and Infectious Diseases Society of America (IDSA) (http://www. idsociety.org/Influenza_Statement.aspx).
Earlier treatment provides better clinical responses. However, treatment after 48 hours of symptoms in adults and children with moderate to severe disease or with progressive disease has been shown to provide some benefit and should be strongly considered. In previous years, the use of double-dose oseltamivir, particularly for those hospitalized with severe illness caused by pH1N1, was believed to provide better outcomes. However, recently published data from a randomized, prospective trial with 75% of subjects younger than 15 years documented no benefit of double-dose therapy over standarddose therapy.
Dosages for antiviral agents for both treatment and chemoprophylaxis in children can be found in Table 3 and on the CDC Web site (http://www.cdc. gov/flu/professionals/antivirals/index. htm). Children younger than 2 years mg, and 75-mg capsules and as a powder for oral suspension that is reconstituted to provide a final concentration of 6 mg/mL. For the 6-mg/mL suspension, a 30-mg dose is given with 5 mL of oral suspension, a 45-mg dose is given with 7.5 mL oral suspension, a 60-mg dose is given with 10 mL oral suspension, and a 75-mg dose is given with 12.5 mL oral suspension. If the commercially manufactured oral suspension is not available, a suspension can be compounded by retail pharmacies (final concentration also 6 mg/mL), based on instructions that are present on the package label. In patients with renal insufficiency, the dose should be adjusted on the basis of creatinine clearance. For treatment of patients with creatinine clearance 10-30 mL/min, administer 75 mg, once daily, for 5 d. For chemoprophylaxis of patients with creatinine clearance 10-30 mL/min, administer 30 mg, once daily, for 10 d after exposure or 75 mg, once every other day, for 10 d after exposure (5 doses). See http://www.cdc.gov/flu/professionals/antivirals/antiviral-drug-resistance.htm. b Approved by the FDA for children as young as 2 wk of age. Given preliminary pharmacokinetic data and limited safety data, oseltamivir can be used to treat influenza in both term and preterm infants from birth because benefits of therapy are likely to outweigh possible risks of treatment. c Oseltamivir dosing for preterm infants. The weight-based dosing recommendation for preterm infants is lower than for term infants. Preterm infants may have lower clearance of oseltamivir because of immature renal function, and doses recommended for full-term infants may lead to very high drug concentrations in this age group. Limited data from the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group provide the basis for dosing preterm infants using their postmenstrual age (gestational age + chronological age): 1.0 mg/kg per dose, orally, twice daily, for those <38 wk postmenstrual age; 1.5 mg/kg per dose, orally, twice daily, for those 38 through 40 wk postmenstrual age; 3.0 mg/kg per dose, orally, twice daily, for those >40 wk postmenstrual age. For extremely premature infants (<28 wk postmenstrual age), consult a pediatric infectious disease physician. d Zanamivir is administered by inhalation using a proprietary "Diskhaler" device distributed together with the medication. Zanamivir is a dry powder, not an aerosol, and should not be are at elevated risk of hospitalization and complications attributable to influenza. The FDA has licensed oseltamivir for children as young as 2 weeks of age. Given preliminary pharmacokinetic data and limited safety data, oseltamivir can be used to treat influenza in both term and preterm infants from birth because benefits of therapy are likely to outweigh possible risks of treatment. As postexposure prophylaxis for family members and close contacts of an infected person if those people are at high risk of complications from influenza For children at high risk and their family members and close contacts, as well as HCP, when circulating strains of influenza virus in the community are not matched with seasonal influenza vaccine strains, on the basis of current data from the CDC and local health departments These recommendations apply to routine circumstances, but it should be noted that guidance may change on the basis of updated recommendations from the CDC in concert with antiviral availability, local resources, clinical judgment, recommendations from local or public health authorities, risk of influenza complications, type and duration of exposure contact, and change in epidemiology or severity of influenza. Chemoprophylaxis is not recommended for infants younger than 3 months, unless the situation is judged critical, because of limited safety and efficacy data in this age group.
Chemoprophylaxis Should Not Be Considered a Substitute for Immunization
Influenza vaccine should always be offered when not contraindicated, even after influenza virus has been circulating in the community. Antiviral medications currently licensed are important adjuncts to influenza immunization for control and prevention of influenza disease; toxicities associated with antiviral agents or indiscriminate use might limit availability. Pediatricians should inform recipients of antiviral chemoprophylaxis that risk of influenza is lowered but still remains while they are taking the medication, and susceptibility to influenza returns when medication is discontinued.
Oseltamivir use is not a contraindication to immunization with IIV (unlike LAIV). For recommendations about treatment and chemoprophylaxis against influenza, see Table 3 . Among some high-risk people, both vaccination and antiviral chemoprophylaxis may be considered. Updates will be available at www.aapredbook.org/flu and www.cdc. gov/flu/professionals/antivirals/index.htm.
FUTURE NEEDS
For the 2014-2015 season, the AAP does not have a preferential recommendation for any type or brand of influenza vaccine over another. This is partly because the supply and distribution of newer vaccines may be limited during the 2014-2015 season. Moreover, postmarketing safety and vaccine effectiveness data are limited, precluding a full risk-benefit analysis of newer versus previously available products. However, such analyses will be performed as data become available, and in the future specific vaccines may be preferentially recommended for particular groups.
A large body of evidence indicates that even children with severe (anaphylactic) allergic reactions to the ingestion of eggs tolerate IIV in a single, age-appropriate dose. If, as expected, safety monitoring continues to show no elevated risk for anaphylactic reactions in egg-allergic recipients of IIV, special precautions regarding allergy consultation and waiting periods after administration to egg-allergic recipients beyond those recommended for any vaccine may no longer be recommended. Studies examining the safety of LAIV in egg-allergic recipients also are ongoing.
Efforts should be made to create adequate outreach and infrastructure to facilitate the optimal distribution of vaccine so that more people are immunized. Pediatricians also should become more involved in pandemic preparedness or disaster planning efforts. A bidirectional partner dialogue between pediatricians and public health decision makers assists efforts to address children' s issues during the initial state, regional, and local plan development stages. Additional information about disaster preparedness can be found at www. aap.org/en-us/advocacy-and-policy/aaphealth-initiatives/children-and-disasters/ Pages/Pediatric-Preparedness-ResourceKit.aspx.
Health care for children is best provided in the medical home, which may have limited capacity to accommodate all patients (and their families) seeking influenza immunization. With the greater demand for immunization during each influenza season, the AAP and the CDC recommend vaccine administration at any visit to the medical home during influenza season when it is not contraindicated, at specially arranged vaccine-only sessions, and through cooperation with community sites, schools, and child care centers to provide influenza vaccine. If alternative venues, including pharmacies and other retail-based clinics, are used for immunization, a system of patient record transfer is beneficial in maintaining the accuracy of immunization records. Immunization information systems should be used whenever available. Two-dimensional barcodes have been used to facilitate more efficient and accurate documentation of vaccine administration, with limited experience to date. Multiple barriers appear to affect influenza vaccination coverage for children in foster care, refugee and immigrant children, and homeless children. Access to care issues, lack of immunization records, and questions about who can provide consent may be addressed by linking children with a medical home, using all health care encounters as vaccination opportunities, and more consistently using immunization registry data.
Cost-effectiveness and logistic feasibility of vaccinating everyone continue to be concerns. With universal immunization, particular attention is being paid to vaccine supply, distribution, implementation, and financing. Potential benefits of more widespread childhood immunization among recipients, their contacts, and the community include fewer influenza cases, fewer outpatient visits and hospitalizations for influenza infection, and a decrease in the use of antimicrobial agents, absenteeism from school, and lost parent work time. To administer antiviral therapy optimally in hospitalized patients with influenza who cannot tolerate oral or inhaled antiviral agents, FDA-approved intravenous NAIs for children also are needed.
Continued evaluation of the safety, immunogenicity, and effectiveness of influenza vaccine, especially for children younger than 2 years, is important. The potential role of previous influenza vaccination on overall vaccine effectiveness by virus strain and subject age in preventing outpatient medical visits, hospitalizations, and deaths continues to be evaluated. Continued assessment of the safety of LAIV is warranted as more children receive the vaccine annually. In addition, the routine use of LAIV in children with certain respiratory and nonrespiratory chronic medical conditions warrants additional consideration. There is also a need for more systematic health service research on influenza vaccine uptake and refusal as well as identification of methods to increase uptake. In addition, development of a safe, immunogenic vaccine for infants younger than 6 months is essential. Until such a vaccine is available for infants younger than 6 months, vaccination of their mothers during pregnancy is the best way to protect these infants. Breastfeeding also is recommended to protect against influenza viruses by activating innate antiviral mechanisms, specifically type 1 interferons. Mandatory annual influenza immunization of all HCP has been implemented successfully at an increasing number of pediatric institutions. Future efforts should include broader implementation of mandatory immunization programs. Optimal prevention of influenza in the health care setting depends on the vaccination of at least 90% of HCP. Additional studies are needed to investigate the extent of offering to immunize parents and adult child care providers in the pediatric office setting; the level of family contact satisfaction with this practice; how practices handle the logistic, liability, legal, and financial barriers that limit or complicate this service; and, most importantly, how this practice will affect disease rates in children and adults. In addition, adjuvants have been shown to increase immune responses to influenza vaccines, but certain adjuvants have been associated with the development of narcolepsy in some studies. Additional studies on the effectiveness and safety of influenza vaccines containing adjuvants are needed. Finally, efforts to improve the vaccine development process to allow a shorter interval between identification of vaccine strains and vaccine production continue.
